Sapho Bio: Funding, Investors & Team (Sep 2026)
Sapho Bio offers rapid RNA-based sterility testing that replaces slow traditional methods by delivering accurate results.
Sapho Bio has raised $5.0M across 1 funding round on record, the most recent a Seed of $5.0M announced in Apr 2026.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Sapho Bio Company Profile and Key Stats
Latest funding round on record: Apr 2026.
Sapho Bio Funding Rounds
Sapho Bio Founders and Leadership Team
No contact details are on record for this team yet.
Sapho Bio Funding Compared to Other Biotechnology Startups
Sapho Bio's latest round of $5.0M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Sapho Bio in Biotechnology and San Carlos
Companies Similar to Sapho Bio
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Sapho Bio Funding FAQs
What does Sapho Bio do?
Sapho Bio offers rapid RNA-based sterility testing that replaces slow traditional methods by delivering accurate results.
How much funding has Sapho Bio raised?
Sapho Bio has raised $5.0M across 1 round on record. The most recent is a Seed of $5.0M announced in Apr 2026.
When did Sapho Bio last raise funding?
Sapho Bio's most recent funding round on record is a Seed of $5.0M, announced in Apr 2026.
Who founded Sapho Bio?
FundedIQ lists Abraham Chaibi (Founder) at Sapho Bio.
Where is Sapho Bio headquartered?
Sapho Bio is based in San Carlos, California, United States.
How many employees does Sapho Bio have?
Sapho Bio is in the 11-50 employee band.
How does Sapho Bio's funding compare to other Biotechnology startups?
Sapho Bio's latest round of $5.0M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Sapho Bio Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Sapho Bio is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.